[p73 polymorphisms and clinicopathologic characteristics in breast cancer]

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Breast cancer is a heterogeneous disease with diverse genetic underpinnings.
• The p73 gene plays a role in tumor suppression and apoptosis.
• Understanding genetic polymorphisms can offer insights into cancer development and progression.

Purpose of the Study:

• To investigate the association between p73 G4C14-A4T14 polymorphisms and the clinicopathological features of breast cancer patients.
• To determine if specific p73 genotypes correlate with breast cancer subtypes and treatment response.

Main Methods:

• Genotyping of 170 breast cancer patients for p73 G4C14-A4T14 polymorphisms using Sequenom MassArray® iPLEX GOLD.
• Statistical analyses including t-tests, chi-squared tests, and logistic regression were employed.
• Correlations were assessed between polymorphisms and patient age, tumor size, clinicopathological characteristics, and chemotherapy efficacy.

Main Results:

• No significant correlation was found between p73 polymorphisms and most clinicopathological characteristics (age, tumor size, menopausal status, TNM stage, etc.).
• A significantly higher frequency of the GC/GC genotype was observed in triple-negative breast cancer patients compared to non-triple-negative cases (78.9% vs. 57.6%, P=0.017).
• P73 polymorphism showed a non-significant negative correlation with chemosensitivity to anthracycline-based chemotherapy.

Conclusions:

• P73 G4C14-A4T14 polymorphisms are positively associated with triple-negative breast cancer.
• The GC/GC genotype in p73 may indicate a worse prognosis for breast cancer patients.
• Further research is warranted to elucidate the functional impact of these polymorphisms on breast cancer development and outcomes.